Profiles and Reports
Profiles and Reports
Battelle Report on Economic Impact
The U.S. biopharmaceutical industry develops medicines that save, sustain and improve lives. The industry is also well recognized as a dynamic and innovative business sector generating high-quality jobs and powering economic output and exports for the U.S. economy. This report quantifies this economic impact of the biopharmaceutical sector on the U.S. economy and jobs. Using input/output analysis, this report measures the direct and indirect impacts of the biopharmaceutical sector, and quantifies the economic impacts that would occur if biopharmaceutical revenues increase or decrease from significant changes in the business operating environment.
Industry Profile 2013
The annual 2013 Pharmaceutical Industry Profile provides an overview of the sector, highlighting the latest medical advances, the impact of biopharmaceutical companies on the economy and the future of innovation.
Our Chart Pack, “Biopharmaceuticals in Perspective,” contains useful facts and figures about prescription medicines and their role in the health care system, as well as in America's overall economy. Bookmark it today.
Recognizing the Value of Innovation in HIV/AIDS Therapy
A new white paper from Boston Healthcare Associates takes a closer look at the remarkable advances we’ve made in the treatment of HIV/AIDS. Progress against HIV/AIDS has occurred through a series of incremental gains in knowledge and discovery, transforming what was once considered an acute fatal illness into a manageable chronic condition for those who have access to treatment.
Recognizing the Value of Innovation in Rheumatoid Arthritis
A new white paper from Boston Healthcare Associates explores the various ways in which additional clinical value has been realized over time for RA patients. As our understanding of the underlying mechanism of the disease grows, and researchers accumulate knowledge regarding the real-world use of many therapies, the treatment paradigm has shifted from aiming for symptom relief to targeting disease remission.
Innovation in the Biopharmaceutical Pipeline: A Multidimensional View
The Biopharmaceutical Pipeline: Evolving Science, Hope for Patients
Biopharmaceuticals in Medicare, Medicaid and Department of Veterans Affairs
Recognizing Value In Oncology Innovation
significant progress in the fight against cancer in the United States. Several organizations report declines in cancer death rates and increases in survival rates for both men and women. New medicines have accounted for 50-60 percent of the increase in cancer survival rates since 1975.
Interactive 2012 Pharmaceutical Industry Profile
Experience the 2012 Pharmaceutical Industry Profile in a new interactive format on your iPad. From your iPad, click here and download the interactive version. You can also download directly through iTunes here.
Driving State Economic Growth in the 21st Century: Advancing the Biopharmaceutical Sector
The biopharmaceutical industry contributes significantly to national, state, and local economies. Recognizing this sector’s contributions to state economies in terms of providing high‐value, high‐wage, revenue‐generating jobs, PhRMA commissioned Battelle to conduct this study to examine the extent to which state governments are targeting the industry for economic growth and development.
Archstone Report on Economic Impact
Despite the economic challenges of recent years, America's biopharmaceutical research companies remain a major source of employment throughout the United States. The sector also contributes to the nation's economy in various ways, including contribution to GDP, taxes, R&D spending, intellectual property, and exports.
Discoverers Award 2011: JANUVIA®
Two Merck research scientists, Nancy A. Thornberry and Ann E. Weber, Ph.D., received the 2011 Discoverers Award, the highest honor from PhRMA. They were recognized for their leadership in the discovery of JANUVIA®, a once-daily pill that helps patients with type 2 diabetes control glucose in conjunction with diet and exercise.
Pharmaceutical Marketing & Promotion
Activities conducted as part of pharmaceutical marketing and promotion are an important part of informing consumers and healthcare professionals about new treatments. This booklet offers facts that we believe are important to consider as the value of marketing and promotion is debated.
New Medicines Approvals in 2012
In 2012, the Food and Drug Administration (FDA) approved 44 new medicines—the largest number in 15 years. Among the medicines were 14 medicines for cancer and cancer-related conditions, including the first medicine approved to treat late-stage basal cell carcinoma (the most common form of skin cancer), three medicines for the treatment of leukemia, and two medicines for the treatment of late-stage colorectal cancer.